In 2017, Chipscreen Biosciences was reported by Nature magazine as a paradigm of “Spotlight on Shenzhen”. In 2007, Chipscreen Biosciences has been reported by Nature.
The article pointed out that in this decade of advancing with the times, Chipscreen Biosciences has been successfully transformed from an enterprise focusing mainly on R&D into one integrating R&D, production, registration, declaration, marketing, commercialization and industrialization. In the fields of such as tumors, metabolic diseases, autoimmune systems, and endocrine, a number of series original new chemical drugs have been established from early research, preclinical to late clinical development. Moreover, the company has actively participated in shaping national pharmaceutical industry policies and undertaken a number of major national science and technology projects. As a pioneer in China’s drug innovation, it has drawn wide attention from the media both at home and abroad!